Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NTS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NTS Recombinant Peptide / NTS-Fc Fusion Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for ligand-binding assays. |
View NTS Products |
| Gene Delivery | NTSR1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Essential for GPCR functional assays. |
View NTSR1 Products |
| Benchmark Ab | Anti-NTS / Anti-NTSR1 Benchmark Antibodies Recombinant positive controls derived from clinical-grade sequences. |
View NTS Products |
| Validator | NTS / NTSR1 siRNA Set Target-specific knockdown verification in tumor cell lines. |
View NTS Products |
| Related Target A | NTSR1 The primary high-affinity GPCR mediating NTS oncogenic signaling and internalization. |
View NTSR1 Products |
| Related Target B | NTSR2 Low-affinity receptor; crucial for counter-screening to ensure off-target safety. |
View NTSR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Retention | Lentivirus-driven stable cell lines preserve the native 7-transmembrane structure of NTSR1/NTSR2 for functional screening. |
| Subfamily Counter-Screening | Highly purified, sequence-verified NTSR1 and NTSR2 target tools prevent off-target cross-reactivity. |
| Lack of Controls | Clinical benchmark antibodies (biosimilars) included for assay calibration and validation. |
| False Positives in Knockdown | Sequence-optimized siRNA pools included for precise target validation in phenotypic assays. |
Live NTS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The neurotensin (NTS) and neurotensin receptor (NTSR) signaling axis has emerged as a high-value therapeutic target, particularly in oncology and progressive neurological disorders. Historically studied for its neurotransmitter functions, NTS is frequently overexpressed in solid tumors—such as pancreatic ductal adenocarcinoma (PDAC), breast, prostate, and colorectal cancers—where it acts via an autocrine/paracrine loop to drive tumor proliferation, metastasis, and chemoresistance.
The race for NTS/NTSR therapeutics is intensifying, with major players shifting focus from traditional small-molecule antagonists to peptide-drug conjugates (PDCs) and radioligand therapies (RLTs). As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective, internalizing NTSR1-targeted vectors designed to deliver cytotoxic or radiolytic payloads directly into the tumor microenvironment while sparing healthy tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Radioligand Therapy (RLT) | 3B Pharmaceuticals, Ipsen, Debiopharm | Pancreatic Cancer, Prostate Cancer, Solid Tumors | Internalization & Trafficking Assay (Requires stable NTSR1-expressing cell lines via Lentivirus) |
| Peptide-Drug Conjugate (PDC) | Univercells, Academic Institutions | Refractory Breast and Ovarian Cancer | Affinity & Binding Kinetics (Requires sequence-verified NTS peptide and receptor orthologs) |
| Small Molecule Antagonists | Shionogi, Sanofi (historical) | Schizophrenia, Pain, Oncology | Selectivity Screening (Requires NTSR1 vs. NTSR2 GPCR counter-screening panels) |